Updated from 11:24 a.m. ESTNearly a dozen patient deaths have been recorded in an ongoing clinical trial of Celgene's (CELG - Get Report) experimental drug Revlimid, TheStreet.com has learned. If confirmed and attributable to the drug, the deaths could delay, or derail, Revlimid's chances for U.S. approval, which would force investors and analysts to reduce forecasts for the company's near-term earnings and sales growth.
Deaths Mar Trial of Celgene Drug
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.